Case Study: Compass Pathways advances COMP360 development with Quotient Sciences human ADME study

Compass Pathways advances COMP360 with Quotient Sciences in a human ADME study

Compass Pathways, a biotechnology company pioneering new mental health treatments, faced the challenge of advancing their investigational COMP360 psilocybin therapy towards regulatory approval. To do this, they needed to conduct a human ADME study to understand how the compound is absorbed, distributed, metabolized, and excreted in the human body. They partnered with Quotient Sciences to undertake this specialized clinical pharmacology work.

Quotient Sciences successfully implemented the solution by administering COMP360 to healthy volunteers in a controlled clinical setting for the human ADME study. This partnership provided Compass Pathways with the critical data on the drug's metabolic profile needed to support its regulatory submission and development pathway.

Compass Pathways